Clinical Trial

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.
Protocol Amendment History 1 change
notable Trial sites expanded: 3 -> 12 locations 2026-07-15
Trial Details
NCT Number NCT07670416
Lead Sponsor Hoffmann-La Roche
Conditions Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM)
Enrollment 300 participants
Start Date 2026-07-03
Primary Completion 2028-02-24 (estimated)
Study Completion 2028-03-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-14